MRK Merck & Co., Inc.
USHealthcareAs of 2026-10-08
Why MRK matters now
Merck & Co., Inc. (MRK) is a US stock in Healthcare. The latest InvestLog snapshot shows $142.40 with -0.28% on the session and $351.69B in market capitalization; recent performance reads 1-month -0.32% and YTD +8.18%.
The latest financial table shown here is Q1 2026, with revenue of $16.29B, net income of $-4.24B, and EPS of $-1.72. Investors can compare that operating picture with valuation signals such as P/E 16.17 and FCF yield 5.0%.
InvestLog's latest related AI research is a Rating Change note titled "Cantor Fitzgerald - Outstanding ESMO Expected raises MRK target to $145". The latest indexable market news headline is "INVA vs. MRK: Which Stock Is the Better Value Option?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $135.00; recent insider activity includes BAKER DOUGLAS M JR filing A-Award; recent congressional disclosure data includes Josh Gottheimer Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
16.17
PEG
2.43
P/B
6.14
P/S
4.29
EV/EBITDA
17.31
DCF Value
$204.04
FCF Yield
5.0%
Div Yield
3.0%
Margins & Returns
Gross Margin
75.9%
Operating Margin
27.6%
Net Margin
13.6%
ROE
17.9%
ROA
6.9%
ROIC
13.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.29B | $-4.24B | $-1.72 |
| Q4 2025 | $16.32B | $2.96B | $1.19 |
| FY 2025 | $64.93B | $18.25B | $7.28 |
| Q3 2025 | $17.18B | $5.79B | $2.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$131.58
Target (Median)
$135.00
Target Range
$100.00 - $150.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Cantor Fitzgerald - Outstanding ESMO Expected raises MRK target to $145Cantor Fitzgerald - Outstanding ESMO Expected 上调目标价 默沙东 (MRK) 至 $145
On 2026-10-08, Cantor Fitzgerald - Outstanding ESMO Expected raised its MRK price target to $145.Cantor Fitzgerald - Outstanding ESMO Expected 于 2026-10-08 将 MRK 目标价上调至 $145。
Scotiabank raises MRK target to $180 from $155Scotiabank 上调目标价 默沙东 (MRK)：$155 → $180
On 2026-09-29, Scotiabank raised its MRK price target to $180 from $155 (+16.1%).Scotiabank 于 2026-09-29 将 MRK 目标价上调至 $180，此前为 $155，变动幅度 +16.1%。
Berenberg raises MRK target to $137Berenberg 上调目标价 默沙东 (MRK) 至 $137
On 2026-09-11, Berenberg raised its MRK price target to $137.Berenberg 于 2026-09-11 将 MRK 目标价上调至 $137。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.22
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.